Brief: Phase 2 Clinical Trial Of Bermekimab Shows Potential New Standard Of Care For Treatment Of Hidradenitis Suppurativa

XBiotech

05/03/2019 13:33

March 5 (Reuters) - XBiotech Inc  XBIT.O :
    * PHASE 2 CLINICAL TRIAL OF BERMEKIMAB SHOWS POTENTIAL NEW
STANDARD OF CARE FOR TREATMENT OF HIDRADENITIS SUPPURATIVA,
INCLUDING SIGNIFICANT PAIN REDUCTION WITHOUT ANTIBIOTICS
    * XBIOTECH - SIGNIFICANT THERAPEUTIC BENEFIT ACHIEVED
WHETHER OR
NOT PATIENTS HAD PREVIOUSLY FAILED TREATMENT WITH EXISTING
FDA-APPROVED BIOLOGICAL DRUG
    * XBIOTECH INC - 61-63% OF PATIENTS ACHIEVED A POSITIVE
HISCR
(ACCEPTED MEASURE OF DISEASE SEVERITY IN HS)

Source text for Eikon:  ID:nGNX4Fr3Hn 
Further company coverage:  XBIT.O 

 ((Reuters.Briefs@thomsonreuters.com;))